Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.

ABSTRACT:

Background

Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechallenge may be associated with improved antitumor responses. However, data are limited on response duration after ICT rechallenge, particularly after severe irAEs.

Objective

To evaluate safety and efficacy of ICT rechallenge after moderate-to-severe irAEs in patients with renal cell carcinoma (RCC), urothelial carcinoma (UC), and prostate cancer.

Methods

In this retrospective cohort study, medical records from September 25, 2013, to June 1, 2020, for patients with genitourinary

SUBMITTER: Siddiqui BA 

PROVIDER: S-EPMC8323401 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature